Pandemic Response Box

Pandemic Response Box

Started in 2019

 

Launched in 2019 by Medicines for Malaria Venture (MMV) and DNDi, the Pandemic Response Box is a collaborative project that aims to accelerate the discovery of new treatments for life-threatening pandemic diseases by providing researchers free access to 400 diverse compounds.

Disease experts selected the Pandemic Response Box’s collection of 201 antibacterial, 153 antiviral, and 46 antifungal compounds for screening against infectious and neglected diseases. The compounds are in various phases of drug discovery or development. In return for receiving the drug-like molecules free of charge, researchers agree to make their screening results publicly available and to publish their findings in an open access journal within two years following data generation.

 

A deeper understanding of disease pathogenesis as well as research into new, effective therapies could prevent the scenario of drug-resistant pathogens emerging and spreading. The goal is to help shorten the time between the emergence of a new pandemic and the availability of new drugs to treat it. History has repeatedly shown that saving time, saves lives.

Graeme Bilbe, R&D Director, DNDi

 

Open and collaborative approaches to medical innovation

MMV and DNDi can provide advice, support, and additional compound quantities to help researchers follow up on interesting findings. The Pandemic Response Box is one of several MMV and DNDopen science projects, which encourage collaboration and transparency in drug development research.

 

How to order

More details on the box and how to order it can be found on the Pandemic Response Box web page.

 

Press release

29 January 2019
MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

 

Partners

Medicines for Malaria Venture (MMV)

 

Factsheet

Coverpage of the Pandemic Response Box Factsheet

Pandemic Response Box
2019

English